Parallel session: Hepatitis B - drug development

 Viral hepatitis

Hall C2
English
Science/Research
12 April 2019 16:00 - 18:00


Presentations

PS-073 Preclinical profile of HBV core protein inhibitor, ABI-H3733, a potent inhibitor of cccDNA generation in HBV infected cells
Richard Colonno - United States
12 April 2019 16:00 - 16:15

Abstract
PS-074 A first-in-class orally available HBV cccDNA destabilizer ccc_R08 achieved sustainable HBsAg and HBV DNA suppression in the HBV circle mouse model through elimination of cccDNA-like molecules in the mouse liver
Lu Gao - China
12 April 2019 16:15 - 16:30

Abstract
PS-075 AAV-delivered IL-21 activates CD8+ T-cells to clear HBV replicon plasmid and cccDNA in mice
zhongliang shen - China
12 April 2019 16:30 - 16:45

Abstract
PS-076 Antiviral activity of JNJ-4964 (AL-034/TQ-A3334), a selective toll-like receptor 7 agonist, in AAV/HBV mice after oral administration for 12 weeks
Florence Herschke - Belgium
12 April 2019 16:45 - 17:00

Abstract
PS-077 Lenvervimab, a monoclonal antibody against HBsAg, can induce sustained HBsAg loss in a chronic hepatitis B mouse model
Jung-Hwan Kim - Korea, Rep. of South
12 April 2019 17:00 - 17:15

Abstract
PS-078 A phase 1b evaluation of HepTcell HBV-specific immunotherapy in nuc-controlled, eAg negative chronic HBV infection
Mark Thursz - United Kingdom
12 April 2019 17:15 - 17:30

Abstract
PS-079 HDV co-infection modifies the immunoproteasome profile of HBV infected hepatocytes leading to increased CD8 T-cell recognition: Implication for immunotherapy
Christine, Y.L. Tham - Singapore
12 April 2019 17:30 - 17:45

Abstract
PS-080 Short term RNA interference therapy in chronic hepatitis B using JNJ-3989 brings majority of patients to HBsAg <100 IU/mL threshold
Man-Fung Yuen - Hong Kong
12 April 2019 17:45 - 18:00

Abstract